CIRRUS (02507) surged over 3% during the trading session. At the time of writing, the stock was up 3.12% to HK$54.5, with a turnover of HK$6.2159 million.

On September 8, CIRRUS was removed from the Hong Kong Stock Connect list. However, on November 6, MSCI announced its November index review results, including CIRRUS in the MSCI Global Small Cap Index.

Western Securities released a research report stating that CIRRUS has passed its peak financial pressure period, with strong confidence in a recovery next year. The company has ample follow-up performance potential, with its G7+ product receiving an enthusiastic market response. Order backlog has shown signs of recovery, and full-year sales are expected to achieve high single-digit growth. Profitability is projected to improve further due to product mix upgrades and economies of scale.

The report emphasized that CIRRUS stands to benefit long-term from the reshoring of U.S. manufacturing, with strong company-specific advantages and high growth certainty. At its current valuation, the stock offers compelling value, presenting an opportunity to invest in a high-quality asset at a discounted price.